Mannose binding protein for use in anti-hiv treatment
CA 2472438 A1 · Owner: Sakamoto, Takashi · Inventors: Keshi, Hiroyuki; Kishi, Yuichiro; Wakamiya, Nobutaka
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It is intended to disclose an anti-HIV agent which contains as the active ingredient a mannose-binding protein (MBP) and efficaciously contributes to the treatment of patients infected with human immunodeficiency virus (HIV) and inhibits the progress of the disease. It is also intended to disclose a method of evaluating an anti-HIV activity exerted by the MBP which involves the step of culturing HIV-infected cells in the presence of the MBP.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 30, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 30, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 30, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.